Suchen
Amarin Corporation PLC
AMRNZur Watchlist hinzufügen
16.370USD
-0.100-0.61%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
343.44MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Amarin Corporation PLC Unternehmen
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Amarin Corporation PLC Informationen
BörsenkürzelAMRN
Name des UnternehmensAmarin Corporation PLC
IPO-datumApr 01, 1993
CEOBerg (Aaron D)
Anzahl der mitarbeiter275
WertpapierartDepository Receipt
GeschäftsjahresendeApr 01
AddresseWeWork One Central Plaza Dame Street
StadtDUBLIN
BörseNASDAQ OMX - NASDAQ BASIC
LandIreland
PostleitzahlD02 K7K5
Telefon35316699020
Websitehttps://amarincorp.com/
BörsenkürzelAMRN
IPO-datumApr 01, 1993
CEOBerg (Aaron D)
Führungskräfte von Amarin Corporation PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
234.16K
+95.00%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
8.42K
+4.75%
Mr. Jonathan N. Provoost
Mr. Jonathan N. Provoost
Executive Vice President, Chief Legal and Compliance Officer, Secretary
Executive Vice President, Chief Legal and Compliance Officer, Secretary
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael Torok
Mr. Michael Torok
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
234.16K
+95.00%
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
8.46K
+5.14%
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
8.42K
+4.75%
Mr. Jonathan N. Provoost
Mr. Jonathan N. Provoost
Executive Vice President, Chief Legal and Compliance Officer, Secretary
Executive Vice President, Chief Legal and Compliance Officer, Secretary
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Amarin Corporation PLC?
Die fünf größten Anteilseigner von Amarin Corporation PLC sind: Dr. David Keenan, Ph.D.
Wie viele Institutionen halten Anteile an Amarin Corporation PLC (AMRN)?
Mit Stand vom 2026Q1 halten 280 Institutionen Anteile an Amarin Corporation PLC, mit einem Gesamtmarktwert von etwa 4.71M, was 22.72% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -402415.00 gestiegen.